Skip to search formSkip to main contentSkip to account menu

recurrent non-small cell lung cancer

Known as: lung cancer, non-oat cell, recurrent, Recurrent Non-Small Cell Cancer of the Lung, Non Small Cell Lung Cancer, Recurrent 
The re-emergence of non-small cell lung carcinoma after a period of remission.
National Institutes of Health

Related topics

Related topics

15 relations
ChestEGFR Gene MutationEGFR geneEpithelial Cells

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer
Background Locoregional recurrence rates for non-small cell lung cancer (NSCLC) remain high, even following curative surgical… 
2013
2013
Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): A phase I study.
8056 Background: Nintedanib (N) is a potent, orally bio-available triple angiokinase inhibitor that targets VEGFRs, PDGFRs and… 
2011
2011
Potential Role of Platelet-Derived Growth Factor Receptor Inhibition Using Imatinib in Combination with Docetaxel in the Treatment of Recurrent Non-small Cell Lung Cancer
Introduction: Platelet-derived growth factor receptor (PDGFR) is expressed in lung cancer and is involved in angiogenesis… 
2007
2007
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment…
PurposeTo evaluate the toxicity profile and pharmacological properties of oral CP-547,632 alone and in combination with… 
2005
2005
Phase I study of an antitumor vaccination using α(1,3) galactosyltransferase expressing allogeneic tumor cells in patients (Pts) with refractory or recurrent non-small cell lung cancer (NSCLC)
2586 Background: Lung cancer remains a leading cause of cancer death. Current treatments have limited impact on outcome. In a… 
Review
2004
Review
2004
Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Several novel biologic agents have been designed to specifically inhibit different aspects of tumor growth and progression. The… 
Review
2003
Review
2003
Gefitinib (Iressa) trials in non-small cell lung cancer.
Review
2002
Review
2002
Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer.
Review
2000
Review
2000
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
1990
1990
Negative phase II study of 5-fluorouracil with high-dose leucovorin in non-small cell lung cancer.
Fourteen patients with inoperable or recurrent non-small cell lung cancer (NSCLC) were treated with 5-fluorouracil (5-FU) plus… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)